PharmaCyte Biotech
PMCB
28 hedge funds and large institutions have $586K invested in PharmaCyte Biotech in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 5 closing their positions.
1.91% less ownership
Funds ownership: 9.01% → 7.1% (-1.9%)
9% less capital invested
Capital invested by funds: $643K → $586K (-$56.9K)
13% less funds holding
Funds holding: 32 → 28 (-4)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.8K |
| 2 |
Jane Street
New York
|
+$14K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$7.48K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$4K |
| 5 |
Barclays
London,
United Kingdom
|
+$145 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$57.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$53.8K |
| 3 |
VF
Virtu Financial
New York
|
-$25K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$15K |
| 5 |
Renaissance Technologies
New York
|
-$13.9K |
PMCB Hedge Fund Activity: Q2 2026 in Review
28 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q2 2026, worth a combined $586K — down 8.9% from $643K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PMCB and 2 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $33.8K. The largest seller was Citadel Advisors, cutting an estimated $57.3K.
- 28 institutional investors held PharmaCyte Biotech (PMCB) as of Q2 2026, down from 32 in Q1 2026.
- Funds reported $586K of PharmaCyte Biotech stock for Q2 2026, down 8.9% quarter-over-quarter.
- 2 funds opened new PharmaCyte Biotech positions in Q2 2026 and 5 closed out, a net change of -3 holders.
- The largest PharmaCyte Biotech buyer in Q2 2026 was Susquehanna International Group, an estimated $33.8K added.
- The largest PharmaCyte Biotech seller in Q2 2026 was Citadel Advisors, an estimated $57.3K sold.
Based on aggregated 13F filings for Q2 2026.